percentage of americans on glp 1 New weight-loss drugs surge in popularity amid obesity surge in US, worldwide A Record Number of Americans

Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophyPubMed [cited 2024 Jul 24]

The SELECT trial demonstrated semaglutide reduces major adverse cardiovascular events by 20% in non-diabetic patients, repositioning GLP-1 drugs as disease-modifying therapies

If appetite suppression and weight loss are minimal, discontinue and consider alternatives

Call your doctor for medical advice about side effects, or report them to the FDA at 1-800-FDA-1088

This product is a food supplement and is not intended to diagnose, treat, cure, or prevent any disease

[DOI] [PMC free article] [PubMed] [Google Scholar] 420.Krieger, J